| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| Domain | GAGE | GAGE12H GAGE1 GAGE4 GAGE5 GAGE13 GAGE6 GAGE12F GAGE12I GAGE2E GAGE12J | 1.38e-27 | 24 | 14 | 10 | PF05831 |
| Domain | GAGE_fam | GAGE12H GAGE1 GAGE4 GAGE5 GAGE13 GAGE6 GAGE12F GAGE12I GAGE2E GAGE12J | 2.30e-27 | 25 | 14 | 10 | IPR008625 |
| Domain | GAGE | 1.22e-12 | 19 | 14 | 5 | SM01379 | |
| Domain | GAGE | 1.22e-12 | 19 | 14 | 5 | IPR031320 | |
| Pubmed | An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members. | GAGE12H GAGE1 GAGE4 GAGE5 GAGE13 GAGE6 GAGE7 GAGE12F GAGE12I GAGE2E GAGE12J | 3.25e-34 | 20 | 16 | 11 | 18179644 |
| Pubmed | 1.12e-22 | 10 | 16 | 7 | 9651357 | ||
| Pubmed | Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. | 3.09e-22 | 11 | 16 | 7 | 10397259 | |
| Pubmed | A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. | GAGE1 GAGE5 GAGE13 GAGE6 GAGE7 GAGE12G GAGE12F GAGE12I GAGE2E GAGE12J | 1.18e-21 | 119 | 16 | 10 | 28625976 |
| Pubmed | 1.30e-15 | 9 | 16 | 5 | 7544395 | ||
| Pubmed | 1.80e-08 | 407 | 16 | 6 | 15772651 | ||
| Pubmed | 1.98e-07 | 2 | 16 | 2 | 30871606 | ||
| Interaction | FLT3 interactions | GAGE1 GAGE5 GAGE13 GAGE6 GAGE7 GAGE12G GAGE12F GAGE12I GAGE2E GAGE12J | 2.28e-16 | 318 | 13 | 10 | int:FLT3 |
| Interaction | GMCL1 interactions | 2.96e-10 | 154 | 13 | 6 | int:GMCL1 | |
| Interaction | GMCL2 interactions | 1.48e-06 | 36 | 13 | 3 | int:GMCL2 | |
| Interaction | GAGE12G interactions | 8.05e-06 | 7 | 13 | 2 | int:GAGE12G | |
| Interaction | EXOC3L2 interactions | 3.48e-05 | 14 | 13 | 2 | int:EXOC3L2 | |
| Interaction | GAGE2E interactions | 2.39e-04 | 36 | 13 | 2 | int:GAGE2E | |
| Interaction | UTP11 interactions | 2.98e-03 | 128 | 13 | 2 | int:UTP11 | |
| Interaction | ZC3H4 interactions | 3.91e-03 | 147 | 13 | 2 | int:ZC3H4 | |
| Interaction | ZC3H13 interactions | 4.50e-03 | 158 | 13 | 2 | int:ZC3H13 | |
| Interaction | DIDO1 interactions | 5.55e-03 | 176 | 13 | 2 | int:DIDO1 | |
| Interaction | PLEKHF2 interactions | 6.44e-03 | 190 | 13 | 2 | int:PLEKHF2 | |
| Interaction | NSRP1 interactions | 6.91e-03 | 197 | 13 | 2 | int:NSRP1 | |
| Cytoband | Xp11.23 | 3.16e-18 | 95 | 16 | 8 | Xp11.23 | |
| Cytoband | Xp11.4-p11.2 | 1.47e-13 | 6 | 16 | 4 | Xp11.4-p11.2 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chrXp11 | 2.56e-11 | 377 | 16 | 7 | chrXp11 | |
| Coexpression | SATO_SILENCED_BY_DEACETYLATION_IN_PANCREATIC_CANCER | 4.50e-07 | 47 | 9 | 3 | M11213 | |
| Coexpression | ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN | 4.57e-06 | 873 | 9 | 5 | M16009 | |
| Coexpression | RAY_TARGETS_OF_P210_BCR_ABL_FUSION_UP | 1.25e-05 | 16 | 9 | 2 | M16309 | |
| Coexpression | DALESSIO_TSA_RESPONSE | 3.39e-05 | 26 | 9 | 2 | M2340 | |
| Coexpression | SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_CANCER_2 | 1.12e-04 | 47 | 9 | 2 | M9702 | |
| Coexpression | SATO_SILENCED_EPIGENETICALLY_IN_PANCREATIC_CANCER | 1.12e-04 | 47 | 9 | 2 | M5542 | |
| ToppCell | TCGA-Kidney-Primary_Tumor-Renal_Cell_Carcinoma-Kidney_Papillary_Renal_Cell_Carcinoma-6|TCGA-Kidney / Sample_Type by Project: Shred V9 | 3.03e-04 | 132 | 9 | 2 | 79b3443c5cfefa172164625a7b2be469311ba2a8 | |
| ToppCell | droplet-Mammary_Gland-nan-21m-Epithelial-nan|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.73e-04 | 165 | 9 | 2 | 7c771f22b58989572c939ed127e637ec28dc0dca | |
| Drug | indene | 4.65e-09 | 120 | 13 | 5 | CID000007219 | |
| Drug | 1ct8 | 2.93e-08 | 173 | 13 | 5 | CID000444888 | |
| Drug | AC1Q6AQ7 | 3.04e-06 | 188 | 13 | 4 | CID000005515 | |
| Drug | 2-methyl-2,4-pentanediol | 3.58e-06 | 196 | 13 | 4 | CID000007870 | |
| Drug | IPEM | 6.31e-06 | 7 | 13 | 2 | CID000126238 | |
| Drug | 4-thiouracil | 1.98e-05 | 12 | 13 | 2 | CID002734394 | |
| Drug | 4-META | 3.15e-05 | 15 | 13 | 2 | CID000051027 | |
| Drug | 1bn3 | 4.07e-05 | 17 | 13 | 2 | CID000001514 | |
| Drug | 1bnn | 5.12e-05 | 19 | 13 | 2 | CID000001604 | |
| Drug | Finish | 7.56e-05 | 23 | 13 | 2 | CID000086133 | |
| Drug | dialuminum | 8.96e-05 | 25 | 13 | 2 | CID006857644 | |
| Drug | AC1L9KOK | 1.30e-04 | 30 | 13 | 2 | CID000447287 | |
| Drug | Al5300 | 1.39e-04 | 31 | 13 | 2 | CID000001611 | |
| Drug | t-MA | 1.48e-04 | 32 | 13 | 2 | CID000011089 | |
| Drug | AC1L96VB | 1.56e-04 | 191 | 13 | 3 | CID000439200 | |
| Drug | AC1O5D5R | 1.57e-04 | 33 | 13 | 2 | CID006482240 | |
| Drug | hafnium | 2.20e-04 | 39 | 13 | 2 | CID000023986 | |
| Drug | Mitoxantrone | 3.33e-04 | 247 | 13 | 3 | ctd:D008942 | |
| Drug | A-U-A | 4.55e-04 | 56 | 13 | 2 | CID005494410 | |
| Drug | hexadecanol | 7.52e-04 | 72 | 13 | 2 | CID000002682 | |
| Drug | tungsten | 1.30e-03 | 95 | 13 | 2 | CID000023964 | |
| Drug | AC1NRA8H | 1.30e-03 | 95 | 13 | 2 | CID005287756 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| MSWRGRSTYYWPRPR | 1 | P0DTW1 | |
| MSWRGRSTYYWPRPR | 1 | O76087 | |
| MSWRGRSTYYWPRPR | 1 | Q4V326 | |
| SWGRWRAMLARTYGP | 6 | P53370 | |
| MSWRGRSTYYWPRPR | 1 | A1L429 | |
| MSWRGRSTYYWPRPR | 1 | P0CL80 | |
| MSWRGRSTYYWPRPR | 1 | P0CL81 | |
| MSWRGRSTYYWPRPR | 1 | A6NDE8 | |
| MSWRGRSTYYWPRPR | 1 | P0CL82 | |
| MSWRGRSTYYWPRPR | 1 | A6NER3 | |
| TMRLLPTRRSYTYWW | 621 | Q92562 | |
| MSWRGRSTYYWPRPR | 1 | Q13070 | |
| MSWRGRSTYYWPRPR | 1 | Q4V321 | |
| MSWRGRSTYYWPRPR | 1 | Q13069 | |
| PVSPSRRWWYRCYAY | 186 | Q8NHL6 | |
| MSWRGRSTYYWPRPR | 1 | P0DSO3 | |
| WMTGRRPSPYWRLTW | 506 | Q96N87 |